Eli Lilly’s experimental Alzheimer’s disease treatment, Kisunla — which slowed decline by up to 35% in clinical trials — has been approved by the FDA, after previously delaying its decision in March, the agency announced July 2.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
